Eight common misconceptions about HIV vaccines that may impede progress in controlling the AIDS epidemic

Future Virology

Volumn 7, Issue 8, 2012, Pages 737-740

  Newman, Peter A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

acceptability of healthcare; early termination of clinical trials; HIV vaccines; implementation science; social sciences; translational research

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL (TOPIC); DISEASE CONTROL; DRUG EFFICACY; DRUG RESEARCH; DRUG SYNTHESIS; DRUG USE; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; LICENCE; PRIORITY JOURNAL; REVIEW; THERAPEUTIC MISCONCEPTION; UNITED STATES;

EID: 84865488653     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.12.60     Document Type: Review

References (23)

1. Hall HI, Song R, Rhodes P et al. Estimation of HIV incidence in the United States. JAMA 300, 520-529 (2008).
2. Gayle HD. Curbing the global AIDS epidemic. N. Engl. J. Med. 348, 1802-1805 (2003). (Pubitemid 36514713)
3. Woolf SH. The meaning of translational research and why it matters. JAMA 299(2), 211-213 (2008).
4. Amesty S, Ompad DC, Galea S et al. Prevalence and correlates of previous hepatitis B vaccination and infection among young drug-users in New York City. J. Community Health 33(3), 139-148 (2008).
5. Matthews JE, Stephenson R, Sullivan PS. Factors associated with self-reported HBV vaccination among HIV-negative MSM participating in an online sexual health survey: A cross-sectional study. Plos One 7(2), E30609 (2012).
6. Stupiansky NW, Alexander AB, Zimet GD. Human papillomavirus vaccine and men: What are the obstacles and challenges? Curr. Opin. Infect. Dis. 25(1), 86-91 (2012).
7. Newman PA, Logie C. HIV vaccine acceptability: A systematic review and meta-analysis. AIDS 24(11), 1749-1756 (2010).
8. Roberts KJ, Newman PA, Duan N, Rudy ET. HIV vaccine knowledge and beliefs among communities at elevated risk: Conspiracies, questions and confusion. J. Natl Med. Assoc. 97(12), 1662-1671 (2005). (Pubitemid 41753113)
9. Danovaro-Holliday MC, Wood AL, LeBaron CW. Rotavirus vaccine and the news media, 1987-2001. JAMA 287(11), 1455-1462 (2002). (Pubitemid 34250511)
10. Newman PA, Seiden D, Roberts K, Duan N. A small dose of HIV? HIV vaccine mental models and risk communication. Health Educ. Behav. 36(2), 321-333 (2009).
11. Singh JA, Mills EJ. The abandoned trials of pre-exposure prophylaxis for HIV: What went wrong? Plos Med. 2(9), E234 (2005).
12. Newman PA. Towards a science of community engagement. Lancet 367(9507), 302 (2006).
13. van der Straten A, van Damme L, Haberer JE, Bangsberg DR. Unraveling the divergent results of PrEP trials for HIV prevention. AIDS 26(7), F13-F19 (2012).
14. Simon AE, Wu AW, Lavori PW, Sugarman J. Preventive misconception: Its nature, presence, and ethical implications for research. Am. J. Prev. Med. 32(5), 370-374 (2007). (Pubitemid 46660442)
15. Allen M, Lau CY. Social impact of preventive HIV vaccine clinical trial participation: A model of prevention, assessment and intervention. Soc. Sci. Med. 66(4), 945-951 (2008). (Pubitemid 351178916)
16. Buchbinder SP, Mehrotra DV, Duerr A et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372, 1881-1893 (2008).
17. Frew PM, Mulligan MJ, Hou SI, Chan K, del Rio C. Time will tell: Community acceptability of HIV research before and after the "Step Study" vaccine discontinuation. J. Clin. Trials 2, 149-156 (2010).
18. Newman PA, Yim S, Daley A et al. "Once bitten, twice shy": Participants perspectives in the aftermath of an early HIV vaccine trial termination. Vaccine 29(3), 451-458 (2011).
19. Newman PA, Logie C, James L et al. "Speaking the dialect": Understanding public discourse in the aftermath of an HIV vaccine trial shutdown. Am. J. Public Health 101(9), 1749-1758 (2011).
20. Essack Z, Koen J, Slack C, Lindegger G, Newman PA. Civil society perspectives on negative biomedical HIV prevention trial results and implications for future trials. AIDS Care doi:10.1080/09540121.656566 (2012) (Epub ahead of print).
21. Newman PA, Lee SJ, Rudy E et al. Preventive HIV vaccine acceptability and behavioral risk compensation among a random sample of high-risk adults in Los Angeles (L.A. VOICES). Health Serv. Res. 44(6), 2167-2179 (2009).
22. Blower SM, McLean AR. Prophylactic vaccines, risk behavior change and the probability of eradicating HIV in San Francisco. Science 265, 1451-1454 (1994). (Pubitemid 24306799)
23. Eaton LA, Kalichman SC. Risk compensation in HIV prevention: Implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Curr. HIV/AIDS Rep. 4(4), 165-172 (2007).